Revance Therapeutics Inc. (NASDAQ:RVNC) shares dropped 3.1% during mid-day trading on Wednesday . The company traded as low as $14.70 and last traded at $14.87, with a volume of 115,049 shares changing hands. The stock had previously closed at $15.34.

RVNC has been the subject of a number of research analyst reports. Brean Capital reiterated a “buy” rating and issued a $48.00 target price on shares of Revance Therapeutics in a research note on Tuesday, May 24th. Zacks Investment Research cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 13th. Guggenheim reiterated a “buy” rating and issued a $55.00 target price on shares of Revance Therapeutics in a research note on Tuesday, June 14th. SunTrust Banks Inc. cut their target price on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, June 14th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $35.00 target price (down previously from $54.00) on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Revance Therapeutics has a consensus rating of “Buy” and an average target price of $39.60.

The firm has a 50-day moving average of $13.80 and a 200-day moving average of $16.88. The company’s market capitalization is $423.56 million.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.02. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.06 million. The company’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities analysts expect that Revance Therapeutics Inc. will post ($3.53) earnings per share for the current fiscal year.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.